Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
BRAF
LOX
recurrence
survival
Journal
Thyroid : official journal of the American Thyroid Association
ISSN: 1557-9077
Titre abrégé: Thyroid
Pays: United States
ID NLM: 9104317
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
7
11
2018
medline:
18
12
2019
entrez:
7
11
2018
Statut:
ppublish
Résumé
The BRAF The prognostic value of LOX and its association with mutated BRAF was analyzed in The Cancer Genome Atlas and an independent cohort. Inhibition of mutant BRAF and the MAPK pathway, and overexpression of mutant BRAF and mouse models of BRAF In The Cancer Genome Atlas cohort, LOX expression was higher in BRAF-mutant tumors compared to wild-type tumors (p < 0.0001). Patients with BRAF-mutant tumors with high LOX expression had a shorter disease-free survival (p = 0.03) compared to patients with a BRAF mutation and the low LOX group. In the independent cohort, a significant positive correlation between LOX and percentage of BRAF mutated cells was found. The independent cohort confirmed high LOX expression to be associated with a shorter disease-free survival (p = 0.01). Inhibition of BRAF The data suggest that BRAF
Sections du résumé
BACKGROUND
The BRAF
METHODS
The prognostic value of LOX and its association with mutated BRAF was analyzed in The Cancer Genome Atlas and an independent cohort. Inhibition of mutant BRAF and the MAPK pathway, and overexpression of mutant BRAF and mouse models of BRAF
RESULTS
In The Cancer Genome Atlas cohort, LOX expression was higher in BRAF-mutant tumors compared to wild-type tumors (p < 0.0001). Patients with BRAF-mutant tumors with high LOX expression had a shorter disease-free survival (p = 0.03) compared to patients with a BRAF mutation and the low LOX group. In the independent cohort, a significant positive correlation between LOX and percentage of BRAF mutated cells was found. The independent cohort confirmed high LOX expression to be associated with a shorter disease-free survival (p = 0.01). Inhibition of BRAF
CONCLUSIONS
The data suggest that BRAF
Identifiants
pubmed: 30398411
doi: 10.1089/thy.2018.0424
pmc: PMC6352555
doi:
Substances chimiques
Protein-Lysine 6-Oxidase
EC 1.4.3.13
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-92Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA172012
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011275
Pays : United States
Références
Cancer. 2005 Apr 1;103(7):1330-5
pubmed: 15739211
Endocr Relat Cancer. 2006 Mar;13(1):257-69
pubmed: 16601293
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20
pubmed: 21220306
Endocrinology. 2012 Feb;153(2):985-94
pubmed: 22202162
Cell. 2015 Apr 9;161(2):319-32
pubmed: 25843629
Cancer. 1994 Apr 15;73(8):2206-12
pubmed: 8156527
Nature. 2015 Jun 4;522(7554):106-110
pubmed: 26017313
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10528-33
pubmed: 16024725
Thyroid. 2013 Nov;23(11):1423-30
pubmed: 23496275
EMBO Mol Med. 2015 Jun 15;7(8):1063-76
pubmed: 26077591
Lancet Oncol. 2013 Sep;14(10):e425-35
pubmed: 23993387
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
J Cell Biochem. 2003 Mar 1;88(4):660-72
pubmed: 12577300
Thyroid. 2014 Apr;24(4):695-704
pubmed: 24262022
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
pubmed: 14602780
Oncotarget. 2015 Apr 20;6(11):9073-85
pubmed: 25940539
Diagn Mol Pathol. 2008 Jun;17(2):118-25
pubmed: 18382358
J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47
pubmed: 20810568
Cancer Res. 2015 Jan 15;75(2):367-77
pubmed: 25488748
Sci Signal. 2014 Mar 25;7(318):ra30
pubmed: 24667377
Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6
pubmed: 17054470
Oncotarget. 2016 Apr 5;7(14):18346-55
pubmed: 26943032
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45
pubmed: 25624498
J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8
pubmed: 23066120
Cancer Res. 2016 Apr 1;76(7):1804-13
pubmed: 26818109
Cancer Res. 2005 May 15;65(10):4238-45
pubmed: 15899815
J Clin Endocrinol Metab. 2007 Jun;92(6):2264-71
pubmed: 17374713
Cancer. 2011 Oct 1;117(19):4390-5
pubmed: 21412762
JAMA. 2013 Apr 10;309(14):1493-501
pubmed: 23571588
Biochem J. 2011 Apr 1;435(1):17-31
pubmed: 21406064
Nature. 2006 Apr 27;440(7088):1222-6
pubmed: 16642001
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97
pubmed: 20418080
Br J Cancer. 2010 Oct 12;103(8):1139-43
pubmed: 20877357
Oncogene. 2017 Aug 24;36(34):4819-4827
pubmed: 28436952
Int J Surg Pathol. 2005 Jan;13(1):1-8
pubmed: 15735849
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Clin Oncol. 2014 Sep 1;32(25):2718-26
pubmed: 25024077
Clin Cancer Res. 2016 Sep 1;22(17):4491-504
pubmed: 27029493
Biochem J. 2007 Aug 15;406(1):105-14
pubmed: 17501721
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9
pubmed: 18682506
Neoplasia. 2014 Oct 23;16(10):845-60
pubmed: 25379021